Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
183,300.00 ^KRW	+0.38%		-1.24%	+1.67%

12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI

Press Releases

FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	11-05	AQ
Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	10-14	AQ
FDA Approves Biocon's Denosumab Biosimilars	09-30	AQ
Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	06-16	PU
Celltrion : Investor Presentation May & June 2025	05-12	PU
Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	04-29	AQ
Celltrion's STEQEYMA, now added to the Costco Member Prescription Program	03-28	AQ
Celltrion Wins Costco Formulary Listing For Its Recently Launched Ustekinumab	03-28	AQ
Celltrion Launches STEQEYMA® (ustekinumab-stba) In The United States	03-26	AQ
U.S. FDA approves Celltrion's OMLYCLO as the first and only biosimilar with interchangeability designation referencing XOLAIR	03-10	AQ
Celltrion : Investor Presentation March & April 2025	03-06	PU
Celltrion : FY2024, 4Q24 Earning Release Celltrion Inc.	02-25	PU
Celltrion Receives EC Approval for Avtozma, a Biosimilar to RoActemra	02-24	AQ
Amgen And Celltrion Settle Denosumab BPCIA Case	01-31	AQ
FDA Approves Celltrion's STEQEYMA (Ustekinumab-stba)	01-09	AQ
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	11-21	AQ
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva	11-07	AQ
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease	16/10/24	AQ
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab	16/10/24	AQ
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year	20/09/24	AQ
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents	16/08/24	AQ
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation	20/06/24	AQ
European Biosimilar Regulatory Update	10/06/24	AQ
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06/24	AQ
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	20/05/24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Press Releases

Filters